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blood was sampled prospectively for baseline expression 
of dihydropyrimidine dehydrogenase (DPD), orotate phos-
phoribosyltransferase (OPRT), thymidine phosphorylase 
(TP), and thymidylate synthase (TS), CYP2A6 gene poly-
morphisms, and 5-FU pharmacokinetics.
Results The ORR and DCR were 41.0 and 76.9%. 
The median PFS, TTF, and OS were 4.13, 3.70, and 
11.40 months. Grade 3–4 AEs occurred in only 13 patients, 
and grade 4 AEs occurred in only 1 of them. High OPRT/
TS and peritoneal metastasis (vs. liver metastasis) indepen-
dently predicted responding. High OPRT/DPD indepen-
dently predicted grade 3–4 AEs. High AUC0–24h of 5-FU 
and metastatic/recurrent sites ≤2 (vs. >3) independently 
predicted prolonged PFS. Low baseline plasmic DPD inde-
pendently predicted prolonged OS.
Conclusions Two-week, oral S-1/LV regimen demon-
strated promising efficacy and safety as first-line chemo-
therapy for AGC.
ClinicalTrials.gov identifier NCT02090153
Keywords Advanced gastric cancer · S-1 · Leucovorin · 
Pharmacogenetic
Background
A globally accepted standard regimen for advanced gastric 
cancer (AGC) has not been established. S-1, a fourth-gen-
eration oral fluorouracil (5-FU), has opened new perspec-
tives with simplicity and convenience over the traditional 
backbone of chemotherapy for AGC, 5-FU.
S-1 contains tegafur/gimeracil/oteracil. Gimeracil 
reduces the degradation of 5-FU by inhibiting dihydro-
pyrimidine dehydrogenase (DPD), and oteracil improves 
its gastrointestinal tolerability by inhibiting orotate 
Abstract 
Background The first one-arm phase II trial aimed to eval-
uate and predict efficacy and safety of S-1 plus oral leuco-
vorin (S-1/LV) as first-line chemotherapy for patients with 
advanced gastric cancer (AGC), using S-1 pharmacogenetic 
pathway approach.
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at conventional dose and LV simultaneously at a dose of 
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phosphoribosyltransferase (OPRT). S-1 plus cisplatin is 
recommended as standard treatment by the Japanese Gas-
tric Cancer Association and has been approved in Asian 
and European countries [1]. However, many patients can-
not tolerant the toxicity of the widely accepted S-1 plus 
platinums [2].
One of the potential partners of S-1 is leucovorin (LV), 
known to enhance the efficacy of 5-FU by forming a ter-
nary complex with 5-FU metabolite and thymidylate syn-
thase (TS) which prolongs the inhibition of TS and blocks 
DNA synthesis. It was proved UFT, a third-generation oral 
5-FU, had favorable activity and tolerability when com-
bined with LV in AGC patients [3]. A phase II study of 
S-1 plus LV (S-1/LV) has demonstrated promising efficacy 
and acceptable safety in patients with metastatic colorectal 
cancer (mCRC) [4]. A randomized phase II study reported 
promising efficacy of S-1/LV and S-1/LV plus oxaliplatin 
(SOL) for AGC, compared with S-1 plus cisplatin [5]. 
However, there has been no one-arm phase I/II study for 
S-1/LV in gastric cancer patients. Interindividual variation 
in pharmacogenetics of the S-1 metabolic pathway can 
affect the extent of S-1 metabolism and impact the efficacy 
and toxicity of S-1-based chemotherapy. Published studies 
all used “candidate” pharmacogenetic factors to predict the 
outcomes of AGC patients with S-1 or S-1-based chemo-
therapy, none of which used S-1 pharmacogenetic pathway 
approach, which means none integrated CYP2A6 polymor-
phism, 5-FU metabolic enzymes, and pharmacokinetics 
at the same time [6–8]. However, those factors do not act 
in isolation. What is more, the results and methods varied 
across studies. Finally, predictive values of these candidates 
might or might not be overcome with drugs combined with 
S-1.
Preclinical studies have highlighted the importance of 
TS, the cellular target of 5-FU–folinic acid mechanism 
of action [9]. Low TS was reported as a predictor of high 
response and long survival for AGC patients with high-dose 
5-FU/LV [10]. In colorectal cancer, both intratumoral TS 
and DPD gene expressions had been reported to be pre-
dictive for the effectiveness of 5-FU/LV or UFT/LV [11, 
12]. However, there was no research on the prediction of 
OPRT, TS, TP, or DPD for efficacy or toxicity of S-1/LV 
or UFT/LV in gastric cancer. What is more, no available 
evidence existed on the predictive potential of CYP2A6 
polymorphism for 5-FU/LV, UFT/LV, or S-1/LV treatment 
in gastric cancer. Interestingly, the use of more than single 
gene expression, such as the combination of low TS with 
high OPRT, or high OPRT/TS had been reported to be even 
more predictive of responders to S-1 or S-1 plus cisplatin in 
gastric cancer patients [13–15].
This current phase II study of S-1/LV is deemed neces-
sary to explore its efficacy and safety as first-line chemo-
therapy for AGC patients. Considering the frequent grade 
3 toxicities, dose reduction, and period prolongation in that 
previous trial of mCRC [4], the 4-week S-1/LV was modi-
fied as 2 week in this study. As the first one, this study used 
S-1 pharmacogenetic pathway approach and integrated 
CYP2A6 polymorphism, DPD, TS, OPRT, thymidine phos-
phorylase (TP), and 5-FU pharmacokinetics to identify the 
subset of patients benefiting more, suffering less from S-1/
LV.
Patients and methods
As a one-arm, single-center, open phase II clinical trial, 
it is approved by the independent Institute Research Eth-
ics Committee at the Sun Yat-sen University Cancer Center 
and conducted in accordance with the Declaration of 
Helsinki.
Patient selection
The eligibility criteria included (1) histologically confirmed 
metastatic or recurrent gastric cancer; (2) at least one meas-
urable lesion; (3) an age of ≥18; (4) adequate oral intake; 
(5) no previous antitumor therapy within 5 years (adju-
vant chemotherapy without S-1 was allowed if finished 
≥6 months before enrollment); (6) an Eastern Cooperative 
Oncology Group performance status <2; and (7) adequate 
bone marrow, hepatic, and renal function.
The exclusion criteria included (1) known hypersensitiv-
ity to any of the study drugs, or usage of drugs interacting 
with S-1; (2) serious concomitant conditions; (3) extensive 
bone, brain, or meningeal metastasis; (4) another synchro-
nous cancer; (5) surgery within 3 months; (6) participating 
in other clinical studies; (7) pregnant women; (8) subjects 
with reproductive potential who were unwilling to use an 
effective method of contraception.
Treatment schedule
S-1 (20-mg capsules) and LV (25-mg tablets) were pro-
vided by DaPeng Co., Ltd, Japan. All patients were orally 
treated with S-1 in doses of 40 mg (body surface area 
(BSA) < 1.25 m2), 50 mg (1.25 ≤ BSA < 1.50 m2) and 
60 mg (BSA ≥ 1.50 m2) b.i.d. in combination with LV 
given simultaneously at a fixed dose of 25 mg b.i.d. on days 
1–7, followed by a 7-day rest.
Response and adverse event assessment
Clinical and laboratory examinations were carried out 
within 7 days before enrollment and each cycle of chemo-
therapy afterward. Tumor measurement was conducted on 
the basis of computed tomographic scans, within 15 days 
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before enrollment and every 3 cycles afterward, according 
to Response Evaluation Criteria in Solid Tumors guidelines 
(version 1.1). Patients were considered response-assess-
able if they had overt clinical or radiological evidence of 
early PD within the first three cycles. All treatment-related 
adverse events (AEs) were categorized according to the 
National Cancer Institute’s Common Terminology Criteria 
for Adverse Events version 4.0 (NCI-CTCAE v4.0).
Blood specimens
Peripheral blood was prospectively, anonymously sampled 
for each patient on the first day of the first cycle at 0 h (pre-
dose) and 0.5, 1, 2, 4, 8, 24 h post-S-1/LV morning dos-
ing. The 2 ml plasma at 0 h was separated for measuring 
baseline protein expression level of DPD, OPRT, TS, and 
TP. The 4-ml blood cells at 0 h were separated for CYP2A6 
gene polymorphism. The 2 ml plasma at 0, 0.5, 1, 2, 4, 8, 
24 h was separated for plasma concentrations of 5-FU.
DPD, OPRT, TS, TP, CYP2A6 gene polymorphism, 
and 5‑FU pharmacokinetics
The plasmic protein expression level of DPD, OPRT, TS, 
and TP was determined by an enzyme-linked immunosorb-
ent assay (ELISA), as described by Cui et al. [7].
Polymerase chain reaction (PCR)–restriction fragment 
length polymorphism were used to determine common 
variant alleles that affect CYP2A6 activity or expression 
in Asian population (CYP2A6*1A, *1D, *9), *13, and the 
wild-type allele (CYP2A6*1), as previously described [16].
Plasma concentrations of 5-FU at 0, 0.5, 1, 2, 4, 8, 24 h 
were measured using negative ion chemical ionization 
gas chromatography mass spectrometry. Pharmacokinetic 
parameters including area under the curve (AUC0–24h), 
maximum concentration (Cmax), time taken to reach maxi-
mum concentration (Tmax), half-time (T1/2), area under the 
first moment curve (AUMC0–24h), mean resistance time 
(MRT0–24h), and plasma clearance (CL) were derived with 
non-compartmental methods using WinNonlin version 3.1 
[17].
Statistical analysis
The primary endpoint of this study was overall response 
rate (ORR), while the secondary endpoints were progres-
sion-free survival (PFS), time to treatment failure (TTF), 
overall survival (OS), disease control rate (DCR), and 
adverse events (AEs).
The sample size for the study was calculated from an 
expected response rate of 40–45% and threshold response 
rate of 20% with α = 0.05 and β = 0.2. Therefore, 31–45 
patients were required in this study.
The Kaplan–Meier method with two-sided log-rank test 
was used to estimate the distribution of time to events. PFS 
was determined from the date of treatment to progression 
(PD) or death from cancer. TTF was determined from the 
date of treatment to PD, death, refusal, or interruption due 
to AEs. OS was calculated from the date of treatment to 
death from any cause or the last date of follow-up. Receiver 
operating characteristic (ROC) curve was used for cutoff 
values of DPD, OPRT, TP, TS, and 5-FU pharmacokinet-
ics in the predictive analyses of response or grade 3–4 AEs. 
X-Tile software was used for cutoff values of them in the 
predictive analyses of survival. Logistic regression was 
used for predictive analyses of response or grade 3–4 AEs, 
and Cox proportional hazards model was used for predic-
tive analyses of survival. Statistical analyses were per-
formed using the SPSS 19.0.
Results
Patient characteristics
Between July 2011 and July 2012, a total of 39 eligible 
patients were enrolled from the Sun Yat-sen University 
Cancer Center. Clinical cutoff date was March 20, 2014. 
The median follow-up was 23.13 months. The baseline 
patient characteristics are summarized in Table 1. The 
median number of treatment cycles was 6 (range 1–20), 
with a total of 252. The median treatment period was 
3.03 months (range 0.47–12.00). The median relative dose 
intensity was 91% for S-1 and 100% for LV.
Overall response rate
All 39 patients were evaluable. No patient had a complete 
response, 16 had partial response (PR), 14 had stable dis-
ease, and 9 had progressive disease. The ORR was 41.0% 
(95% confidence interval (CI) 24.9–57.2%), and the DCR 
was 76.9% (95% CI 63.1–90.8%). The median time to 
response was 1.70 (range 1.40–3.00) months (m).
Survival
The median PFS was 4.13 (95% CI 3.44–4.83) m. The 
median TTF was 3.70 (95% CI 2.60–4.80) m. The median 
OS was 11.40 (95% CI 7.76–15.05) m (Fig. 1).
Adverse events, feasibility, and compliance of treatment
Major AEs included myelosuppression (74.4%), gastro-
intestinal reactions (89.7%), and pigmentation (53.8%); 
however, they were generally mild and no treatment-
related deaths occurred. Anemia (71.8%) was common, and 
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thrombocytopenia was rare (0%). Anorexia (64.1%) was 
common, and diarrhea was not. Grade 3 AEs occurred in 
13 patients (33.3%), and grade 4 AEs occurred in 1 of them 
Table 1  Baseline patient characteristics
Characteristics S-1 plus LV (N = 39)
No. %
Gender (male/female) 28/11 71.8/28.2
Age (years, median, range) 55 (21–83)
Body surface area (m2, median, range) 1.51 (1.33–1.94)
ECOG performance status = 1 39 100
Primary tumor location
 Proximal 11 28.2
 Body 7 17.9
 Antrum 10 25.6
 Multiple/diffuse 11 28.2
Histology
 Well differentiated 3 7.7
 Moderately differentiated 7 17.9
 Poorly differentiated 24 61.5
 Mucinous 4 10.3
 Signet-ring cell 1 2.6
Lauren classification
 Diffuse type 4 11.1
 Intestinal type 13 33.3
 Mixed type 22 55.6
Her-2 gene type
 Positive 6 15.4
 Negative 33 84.6
Site of metastases
 Liver 14 35.9
 Lung 3 7.7
 Lymph nodes 29 74.4
 Peritoneum 14 35.9
 Bone 4 10.3
No. of metastatic/recurrent sites
 1 18 46.2
 2 16 41.0
 3 5 12.8
Prior surgery
 Curative gastrectomy 8 20.5
 Palliative gastrectomy/metastectomy 5 12.9
 Exploration/bypass 4 10.3
 No 22 56.4
Prior adjuvant chemotherapy
 Yes 6 15.4
 No 33 84.6
Fig. 1  Kaplan–Meier curves for the entire population. a Progression-
free survival, b time to failure, and c overall survival
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(2.6%). Each type of the grade 3–4 AEs occurred in only 
1–3 patients, with gastrointestinal reactions in 15.4% and 
myelosuppression in 10.3% (Table 2).
The main reasons for S-1 dose decrease in the 3 patients 
(7.7%) were grade 3 diarrhea, anorexia, and stomatitis, 
respectively. The main reasons for dose interruption in the 
3 patients (7.7%) were grade 3 vomiting, abdominal pain, 
and liver enzyme elevation, respectively. The median num-
ber of chemotherapy cycles before S-1 dose decrease and 
interruption was 4 (range 2–6) and 5 (range 2–10), respec-
tively. Course was prolonged by 7 days until the grade 3 
liver enzyme elevation decreased to grade 1 in 1 patient. 
Five patients (12.8%) discontinued treatment before pro-
gression not due to AEs, with a median number of treat-
ment cycles as 3 (range 1–6) (supplementary Table S1). 
Second-line treatment was given to 21 (53.9%) of the 39 
patients, among whom 5.1% received palliative surgery 
while 48.8% received oxaliplatin-based, irinotecan-based, 
or taxane-based chemotherapy (supplementary Table S2).
Clinical prediction of efficacy and toxicity
For the entire population, baseline plasmic protein expres-
sion of DPD, OPRT, TP, TS and their ratios OPRT/DPD, 
OPRT/TP, OPRT/TS, OPRT/TP + TS, OPRT/DPD + TP, 
OPRT/DPD + TS, and OPRT/DPD + TS + TP are 
summarized in supplementary Table S3. The genotypes and 
allele frequencies of CYP2A6 are shown in supplementary 
Table S4. Mean plasma concentration–time curve of 5-FU 
for the entire population is shown in supplementary Figure 
S1. The AUC0–24h, Cmax, Tmax, T1/2, AUMC0–24h, MRT0–24h, 
CL were determined for each patient and for the entire 
population.
Prediction of response
There were 16 responders and 23 non-responders. By mul-
tivariate logistic regression analysis, high OPRT/TS (>1.246 
vs. ≤1.246, odds ratio (OR) 16.962, 95% CI 1.781–161.581, 
P = 0.014) and peritoneal metastasis (vs. liver metastasis, 
OR 25.604 (1.852–353.979), P = 0.016) were indepen-
dently predictive of responding. OPRT/TS differed between 
responders and non-responders (median ± SD 1.442 ± 0.091 
vs. 1.158 ± 0.133, P = 0.037) and response rates differed 
between patients with high OPRT/TS and low OPRT/TS 
(>1.246 vs. ≤1.246, 57.1 vs. 22.2%, P = 0.040). Figure 2a 
shows the ROC curve of OPRT/TS for predicting response.
Prediction of grade 3–4 adverse events
Thirteen patients experienced grade 3–4 AEs and 
26 patients did not. By univariate logistic regression 
Table 2  Adverse events Adverse events S-1 plus LV (N = 39)
Grade 1 (%) Grade 2 (%) Grade 3 (%) Grade 4 (%) All grade (%)
Leukopenia 6 (15.4) 7 (17.9) 1 (2.6) 0 14 (35.9)
Neutropenia 4 (10.3) 7 (17.9) 1 (2.6) 1 (2.6) 12 (33.3)
Anemia 17 (43.6) 10 (25.6) 1 (2.6) 0 28 (71.8)
Thrombocytopenia 0 0 0 0 0
Asthenia 9 (23.1) 0 0 0 9 (23.1)
Anorexia 19 (48.7) 5 (12.8) 1 (2.6) 0 25 (64.1)
Nausea 11 (28.2) 1 (2.6) 0 0 12 (30.8)
Vomiting 3 (7.7) 2 (5.1) 1 (2.6) 0 6 (15.4)
Diarrhea 9 (23.1) 1 (2.6) 1 (2.6) 0 11 (28.2)
Abdominal pain 5 (12.8) 4 (10.3) 2 (5.1) 0 11 (28.2)
Skin rash 5 (12.8) 0 0 0 5 (12.8)
Hand–foot syndrome 3 (7.7) 1 (2.6) 0 0 4 (10.3)
Pigmentation 16 (41.0) 5 (12.8) 0 0 21 (53.8)
Stomatitis 6 (15.4) 3 (7.7) 1 (2.6) 0 10 (25.6)
Blurred vision 4 (10.3) 0 0 0 4 (10.3)
Lacrimation increased 4 (10.3) 0 0 0 4 (10.3)
Tinnitus 1 (2.6) 0 0 0 1 (2.6)
ALT elevation 4 (10.3) 2 (5.1) 3 (7.7) 0 9 (23.1)
AST elevation 4 (10.3) 1 (2.6) 2 (5.1) 0 7 (17.9)
Hypoalbuminemia 12 (30.8) 2 (5.1) 0 0 14 (35.9)
Proteinuria 1 (2.6) 0 0 0 1 (2.6)
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analysis, high OPRT (accuracy 79.0%), high OPRT/
DPD (80.8%), high OPRT/TP (77.8%), high OPRT/
TS (71.0%), high OPRT/DPD + TP + TS (78.7%), 
high OPRT/DPD + TS (77.8%), high OPRT/TP + TS 
(77.2%), and high OPRT/DPD + TP (80.1%) were all 
associated with grade 3–4 AEs. OPRT/DPD exhibited the 
highest accuracy (80.8%). By multivariate logistic regres-
sion analysis, high OPRT/DPD [>0.754 vs. ≤0.754, OR 
15.566 (1.490–162.605), P = 0.022] was independently 
predictive of grade 3–4 AEs. The rates of grade 3–4 AEs 
differed between patients with high OPRT/DPD and 
low OPRT/DPD (>0.754 vs. ≤0.754, 55.0 vs. 10.5%, 
P = 0.006). Figure 2b shows the ROC curve of OPRT/
DPD for predicting grade 3–4 AEs.
Prediction of progression‑free survival and time to failure
Multivariate analysis with a Cox proportional hazards 
model demonstrated that high AUC0–24h of 5-FU and met-
astatic/recurrent sites ≤2 (vs. >3) were significant predic-
tors of prolonged PFS (supplementary Table S5). Similarly, 
multivariate analysis demonstrated high AUC0–24h of 5-FU 
was borderline significant predictor of prolonged TTF (sup-
plementary Table S6).
The median PFS differed significantly between patients 
with high and low AUC0–24h of 5-FU (5.40 vs. 3.70 m, 
P = 0.022, Fig. 3a), and the median TTF differed border-
line between patients with high and low AUC0–24h of 5-FU 
(4.13 vs. 3.10 m, P = 0.054, Fig. 3b).
Fig. 2  a ROC curve of OPRT/TS for predicting response and b 
the ROC curve of OPRT/DPD for predicting grade 3–4 AEs. ROC 
receiver operating characteristic, OPRT orotate phosphoribosyltrans-
ferase, TS thymidylate synthase, DPD dihydropyrimidine dehydroge-
nase, AEs adverse events
Fig. 3  a Kaplan–Meier curve of progression-free survival according 
to AUC0–24h of 5-FU and b the Kaplan–Meier curve of time to failure 
according to AUC0–24h of 5-FU. AUC areas under the curve
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Prediction of overall survival
Lower baseline plasmic DPD [>119.200 vs. ≤119.200, 
harzard ratio (HR) 2.931 (1.155–7.433), P = 0.024] was 
significantly independent predictor of prolonged OS (sup-
plementary Table S7; Fig. 4).
To integrate the above predictors, we classified 39 
patients into 4 patients with high OPRT/TS, high AUC0–
24h of 5-FU, low DPD (ORR 50.0%, median PFS 7.00 m, 
median OS 13.90 m), and other 35 patients (ORR 40.0%, 
median PFS 4.10 m, median OS 9.17 m).
Discussion
To our knowledge, the current study is the first one-arm and 
the second phase II trial to evaluate efficacy and toxicity 
of S-1/LV chemotherapy in AGC patients, which is the first 
to predict outcomes using S-1 pharmacogenetic pathway 
approach, on the basis that LV is but a cofactor entering the 
5-FU metabolism. The enrollment was between July 2011 
and July 2012, which was similar to between October 2011 
and December 2012 of that randomized phase II study of 
S-1/LV versus SOL versus SP for AGC [5].
We reported S-1/LV regimen yielded promising ORR, 
PFS, TTF, and OS, without combination with platinum, 
taxane, irinotecan, or trastuzumab as first-line treat-
ment. In previous phase II studies of S-1 monotherapy 
in AGC and previous S-1 monotherapy arms of phase 
III JCOG9912 study, SPIRITS study, SC-101 study, 
GC0301/TOP-002 study, and START study, conventional 
dose for 4 weeks followed by 2-week rest was usually 
given [18–22]. The 2-week S-1/LV here was generally 
more effective, with a less dose intensity than S-1 mono-
therapy in these studies. LV can enhance the efficacy of 
5-FU by maintaining the plasma 5-FU concentration [23]. 
Similarly with the previous trial of S-1/LV in mCRC [4], 
S-1/LV regimen here also demonstrated better efficacy 
and safety compared with previously reported UFT/LV 
in AGC [3, 24]. S-1/LV also showed more potential than 
5-FU/LV plus oxaliplatin that we reported in terms of effi-
cacy and safety [25].
To reduce the duration of effective drug concentration 
and keeping an appropriate rest period could be effective 
method of improving safety. So we modified the sched-
ule as 1-week S-1/LV, followed by 1-week rest period, the 
same as S-1/LV group in that randomized phase II study. 
The efficacy S-1/LV here was quite comparable with S-1/
LV group in that randomized phase II study, in terms of 
ORR (41.0 vs. 43%), PFS (4.13 vs. 4.2 m), and TTF (3.70 
vs. 4.1 m) [5]. Fewer patients in our study received the 
second-line treatment (53.9 vs. 77%), which helped explain 
the relatively not so promising OS. Another reason was 
that there were 5 patients discontinuing treatment before 
progression not due to adverse events. Meanwhile, S-1/
LV in this study saw very satisfactory safety. The frequen-
cies of each type of AEs were generally lower than those 
in the phase II trial of mCRC and comparable with those 
in the randomized phase II trial of AGC [4, 5]. Encourag-
ingly, grade 4 AEs occurred in 1 patient (2.6% neutrope-
nia), similarly for the randomized study (2% grade 4 neu-
tropenia and 2% leucopenia). Each type of the grade 3 AEs 
occurred in only 2.6–7.7% patients, similar to 2–13% for 
the randomized study [5]. In our study, significantly fewer 
patients experienced dose reduction, or delayed courses 
[4], compared to patients with S-1 monotherapy in pre-
vious phase III trials [19, 26]. In our study, gastrointesti-
nal reactions were more common than myelosuppression 
both in total (89.7 vs. 74.4%) and in grade 3–4 (15.4 vs. 
10.3%), and dose reductions or interruptions were chiefly 
due to diarrhea, stomatitis, anorexia, and vomiting. We also 
observed dose-limiting toxicity was shifted from hemato-
logical to gastrointestinal when S-1 was administered with 
LV [4]. Probably the capacity of oral intake and gastroin-
testinal tolerability would be the important indications for 
this regimen.
Japan Gastric Cancer Association guideline states that 
S-1 alone could be considered for patient who is not suit-
able for S-1 plus cisplatin therapy [27]. Previous studies 
showed S-1 monotherapy could be a reasonable option in 
the treatment of elderly patients. In our study, the ORR, 
PFS, OS were sound for patients of age >70 (47.1%, 6.00, 
11.40 m) without difference compared with those of age 
≤70 (36.4%, 4.00, 11.20 m) and seemed better than pre-
viously reported S-1 monotherapy (ORR 14.3–26.3%) and 
UFT/LV (ORR 22%) for elderly AGC patients [28–30]. 
The oral convenience makes the S-1/LV regimen extremely 
useful clinically, especially for elderly patients.
Fig. 4  Kaplan–Meier curve of overall survival according to baseline 
plasmic DPD expression. DPD dihydropyrimidine dehydrogenase
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Genotyping the peripheral blood for CYP2A6 polymor-
phism, quantifying plasmic protein expression of DPD, TS, 
TP, and OPRT with ELISA, is more optimal, convenient, 
quicker than evaluating genes, mRNAs, or proteins in tumor 
tissue, especially when 5-FU plasmic pharmacokinetics 
were to be integrated at the same time. Thus, there may be 
more clinical accessibility and prospects. What is more, the 
cutoff levels were determined by standard statistic analysis, 
not the simple median or mean. The plasmic expression of 
DPD in this study was consistent with previously reported 
with ELISA; however, no report for plasmic OPRT, TP, or 
TS was available [7]. The frequencies of CYP2A6 alleles 
in this population were compatible with other Asian popu-
lation [31–33]. We especially examined the CYP2A6*13, 
because its function in Asian patients was unclear. The 0% 
of CYP2A6*13 again proved it is rare in Asia.
In clinical setting, numerous studies have reported a low 
TS, low TP, or a high OPRT expression contributed to a 
high sensitivity to UFT, S-1, or S-1-based treatment in gas-
tric cancer patients, with or without influencing the PFS or 
OS [34–38]. There were also evidences that low TS was a 
predictor of high response for AGC patients with 5-FU/LV, 
or 5-FU/LV plus cisplatin/oxaliplatin [10, 39, 40]. How-
ever, most studies failed to find the DPD expression related 
to either response, PFS, or OS and less studies did demon-
strate high DPD mRNA was predictor of poor OS, not ORR 
or PFS in AGC [35, 41, 42]. These clinical findings reflect 
theoretical roles of TS and OPRT. We found high OPRT/
TS alone significantly predicted responding. The resultant 
high OPRT/TS here revealed preferential use of the OPRT 
pathway versus TS pathway during 5-FU metabolism. In 
humans, the preferential use of the OPRT pathway was 
revealed to correlate with a higher sensitivity to 5-FU [43]. 
Ichikawa et al. and Tanemura et al. [13, 14] both reported 
the combination of high OPRT and low TS was more pre-
dictive of responders to S-1 or S-1 based chemotherapy in 
gastric cancer patients than either alone, while the low TP 
was not. Apart from the above PCR or ELISA methods, 
the quantitative double-fluorescence immunohistochemis-
try method, reported by Hashiguchi K, was used to access 
the protein expressions and their ratios quantitatively and 
found a significant correlation between OPRT/TS, OPRT/
DPD, or OPRT/(TS + DPD) and response to S-1 in the 
AGC patients, among which OPRT/TS showed the strong-
est correlation with the clinical response [15]. These three 
studies generally agree with our finding.
In this current study, low baseline plasmic DPD was not 
related to response; however, it was related to long OS, 
compatible with previous study that high intratumoral DPD 
mRNA was predictor of poor OS, not ORR or PFS [41]. 
Previous studies reported clinical response to S-1 in gastric 
cancer was not influenced by intratumoral DPD expression 
[42]. It can be explained that S-1 has antitumor activity 
even in tumor with high expression of DPD because of 
the inhibition of DPD by CDHP [44]. Even though it had 
no prediction of response, low DPD did relate to long 
OS. Firstly, S-1 enabled high 5-FU concentrations to be 
maintained in blood for long periods of time by inhibiting 
of DPD and 5-FU maintenance was a reason of long sur-
vival. Secondly, low levels of intratumoral DPD have been 
generally shown to predict long survival in gastric cancer 
patients treated with 5-FU-based chemotherapy [45]. Many 
patients here received second-line chemotherapy compris-
ing of 5-FU with platinum or other drugs.
We found plasmic OPRT (P = 0.024), TS (P = 0.044) 
expression significantly inversely, while DPD (P = 0.073), 
TP (P = 0.080) borderline inversely correlated with 
AUC0–24h of 5-FU. The number of CYP2A6 gene vari-
ants (P = 0.889) did not correlate with AUC0–24h. This was 
consistent with that CYP2A6 gene correlated with tegafur 
pharmacokinetics, but not with 5-FU pharmacokinetics 
[16]. AUC0–24h of 5-FU, not OPRT/TS, was predictive of 
PFS revealed that other factors may also influence PFS by 
AUC0–24h of 5-FU. We did not demonstrate the number of 
CYP2A6 gene variants correlated with efficacy. Although 
some studies demonstrated patients having fewer CYP2A6 
variants had better PFS in AGC patients with S-1 plus cis-
platin, or S-1 plus docetaxel [6, 46], divergences on the 
relation between CYP2A6 genetic polymorphisms and 
response existed for both gastric and colorectal cancer 
patients with S-1 or S-1-based chemotherapy [47, 48]. In 
our study, second-line treatment excluded S-1 and tegafur. 
CYP2A6 converts enzymatically tegafur, the effector mol-
ecule of S-1, to 5-FU, and this role produces no meaning 
on second-line treatment.
That high OPRT predicted grade 3–4 AEs as well as 
affected response can be theoretically understood, and 
in animal models, oteracil in S-1 was found to inhibit the 
OPRT by 70% in the small intestine; however, the inhibi-
tion was limited to 0–20% in tumor regions without affect-
ing the antitumor activity of 5-FU. Besides, high OPRT/
DPD, OPRT/TP, OPRT/TS, OPRT/DPD + TP + TS, 
OPRT/DPD + TS, OPRT/TP + TS, and OPRT/DPD + TP 
were all associated with grade 3–4 AEs, among which, 
high OPRT/DPD exhibited the highest accuracy. Cui et al. 
[7] reported lower baseline plasmic DPD correlated with 
higher grade of toxicities in AGC patients with S-1 plus 
docetaxel by ELISA. Further studies were warranted to 
decide whether OPRT or OPRT/DPD better predicts grade 
3–4 AEs. The literature shows severe diarrhea was dose-
limiting toxicity for S-1 in Caucasians and severe neutro-
penia in East Asians perhaps due to CYP2A6 gene poly-
morphism [17], while this study did not see its relation to 
severe diarrhea, neutropenia, or total grade 3–4 AEs and 
no relation of CYP2A6 gene polymorphism to AUC0–24h or 
Cmax of 5-FU here helped explain.
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Conclusion
The 2-week S-1/LV regimen demonstrated promising effi-
cacy and satisfactory safety as first-line chemotherapy for 
AGC. To balance both the efficacy and toxicity, S-1 phar-
macogenetic pathway may help find an optimal subset of 
patients with high OPRT/TS, high AUC0–24h of 5-FU, low 
DPD that may benefit more from S-1/LV, which awaits val-
idation in another large and well-defined population.
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